MedPage Today (9/12, Monaco) reports, “Care for new depression was more commonly delivered by primary care providers (PCPs) than psychiatric” clinicians, investigators concluded in findings presented in a poster at Psych Congress 2023. The “review of adults newly diagnosed with major depressive disorder, 16,987 patients were under the care of a PCP compared with 1,780 who were managed by a psychiatrist at the time of diagnosis, and only 6.2% of PCP-managed patients transitioned to a psychiatrist for their care,” the study found.

Related Links:

— MedPage Today (requires login and subscription)

According to HealthDay (9/12, Mozes), “new research indicates that the more inactive seniors are, the higher their risk for dementia,” investigators concluded after examining “the onset of dementia among nearly 50,000” citizens of the UK who “were at least 60 years old when information about typical daily activity routines was entered into the UK Biobank database at some point between 2006 and 2010.” The study revealed that “seniors who clocked 12 hours a day of inactivity – be it at one stretch, or over 24 hours – saw their risk for dementia spike by 63%,” while “those who sat around for 15 hours a day had a stunning 320% increase in dementia risk.” The findings were published in JAMA.

Related Links:

— “Dementia Risk Rises as Activity Rates Fall,”Alan Mozes, HealthDay, September 12, 2023

According to MedPage Today (9/12, DePeau-Wilson), psychiatric care professionals “most often ranked the side effect profile of long-acting injectables (LAIs) for schizophrenia as the top consideration when prescribing the antipsychotics to patients,” researchers concluded in the findings of a 380-respondent, “survey-based study” presented in a poster at Psych Congress 2023. Among those respondents, “33% cited the safety/tolerability profile as key when selecting an LAI, with 16% to 21% of the respondents citing patient preference, the particular molecule in the LAI, access, or product attributes like dosing intervals or injection site as most important.”

Related Links:

— MedPage Today (requires login and subscription)

MedPage Today (9/11, DePeau-Wilson) reports, “Every-six-month dosing of the long-acting injectable paliperidone palmitate (Invega Hafyera) for schizophrenia was effective and safe up to three years, researchers reported” in “an intention-to-treat analysis that included 121 patients.” The study revealed that “95.9% on the twice-a-year dose of the atypical antipsychotic remained relapse-free.” The findings were presented in a poster at Psych Congress 2023.

Related Links:

— MedPage Today (requires login and subscription)

MedPage Today (9/11, DePeau-Wilson) reports, “People with narcolepsy frequently had mood and pain comorbidities that complicated diagnosis and treatment plans,” investigators concluded. In “a propensity-matched cohort analysis of more than 4,000 individuals,” researchers found that “people with narcolepsy were more than twice as likely to be diagnosed with depression” or “chronic pain syndrome.” The findings were presented at Psych Congress 2023.

Related Links:

— MedPage Today (requires login and subscription)